Filing Flows › Tela Bio (TELA) › Q1 2026 › vs Q4 2025
Tela Bio (TELA) Q1 2026 vs Q4 2025 (quarter over quarter)
Tela Bio's revenue fell $1.8M (-9%) from $20.9M in Q4 2025 to $19.1M in Q1 2026.
Tela Bio, Q1 2026: revenue $19.1M (+3% year over year), operating margin -55.2%, net loss $12.3M, operating cash flow −$11.2M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $19.1M | $20.9M | −$1.8M | -9% |
| Net loss | $12.3M | $9.0M | $3.2M | +36% |
| Costs & expenses | $31.3M | $29.9M | $1.4M | +5% |
| Operating costs | $29.6M | $27.5M | $2.1M | +8% |
| Interest & other, net | $1.7M | $2.2M | −$561K | -25% |
| Income tax | $60K | $145K | −$85K | -59% |
| Cost of revenue | $6.5M | $7.1M | −$575K | -8% |
| Research & development | $2.3M | $2.1M | $214K | +10% |
| Sales & marketing | $16.5M | $14.5M | $2.0M | +14% |
| General & admin | $4.2M | $3.8M | $382K | +10% |
| Operating cash sources | $12.3M | $9.0M | $3.2M | +36% |
| Depreciation | $169K | $130K | $39K | +30% |
| Share-based compensation | $816K | $812K | $4K | +0.5% |
| Working capital & other | $118K | $3.2M | −$3.1M | -96% |
| Cash used in operations | $11.2M | $4.9M | $6.3M | +129% |
| Net loss absorbed | $12.3M | $9.0M | $3.2M | +36% |
Questions
How much did Tela Bio's revenue grow quarter over quarter in Q1 2026?
Tela Bio's revenue fell $1.8M (-9%) from $20.9M in Q4 2025 to $19.1M in Q1 2026.